New Delhi, April 13 (IANS) Indian drugmakers Glenmark Pharmaceuticals, Sun Pharmaceutical Industries, and Zydus are recalling several medicines from the US market due to manufacturing-related problems, according to a latest report by the US Food and Drug Administration (FDA).
Mumbai-based Glenmark is recalling over 25 products from the US due to deviations from current good manufacturing practices (CGMP).
Its US arm, Glenmark Pharmaceuticals Inc., based in New Jersey, is pulling back several medicines, including Propafenone Hydrochloride extended-release capsules and Solifenacin Succinate Tablets.
Other recalled medicines include Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets, and Rufinamide Tablets. The company began this Class II recall on March 13 this year.
According to the USFDA, a Class II recall is issued when using the product may cause temporary or medically reversible health issues. However, the chances of serious health problems are low.
Another Indian pharma company, Sun Pharmaceutical Industries, is also recalling a product in the US. Its US-based unit, Sun Pharmaceutical Industries Inc., has recalled around 13,700 bottles of Gabapentin capsules.
These capsules are used to treat and prevent seizures in people with epilepsy. The recall was initiated due to concerns of ‘cross-contamination.’
This Class III recall started on March 4, 2025. A Class III recall is considered the least serious and is made when the use of a product is not likely to cause harm.
Meanwhile, Zydus Pharmaceuticals (USA) Inc., a subsidiary of Zydus, is recalling 3,144 bottles of Chlorpromazine Hydrochloride Tablets.
These tablets are used for treating mental health conditions such as schizophrenia and bipolar disorder.
The USFDA said the recall was due to the presence of an impurity, N-Nitroso-Desmethyl Chlorpromazine, found above the acceptable limit. The company began this Class II recall on April 3.
The USFDA regularly monitors the safety and quality of medicines sold in the US and ensures that drugmakers follow strict manufacturing standards.
–IANS
pk/uk
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
